The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk

被引:335
|
作者
Staessen, JA
Wang, JG
Ginocchio, G
Petrov, V
Saavedra, AP
Soubrier, F
Vlietinck, R
Fagard, R
机构
[1] Katholieke Univ Leuven, Hypertens & Cardiovasc Rehabil Unit, Dept Mol & Cardiovasc Res, B-3001 Louvain, Belgium
[2] Chinese Acad Med Sci, Fu Wai Hosp, Beijing 100037, Peoples R China
[3] Chinese Acad Med Sci, Dept Hypertens, Cardiovasc Inst, Beijing 100037, Peoples R China
[4] Univ Padua, Dept Expt Med, Med Clin 1, Padua, Italy
[5] INSERM, U358, Paris, France
[6] Katholieke Univ Leuven, Ctr Human Genet, B-3001 Louvain, Belgium
关键词
angiotensin II converting enzyme; cardiomyopathy; coronary heart disease; genetic polymorphism; hypertension; left ventricle; nephropathy; stroke;
D O I
10.1097/00004872-199715120-00059
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Objective This meta-analysis attempted to derive pooled estimates for the associations between various cardiovascular-renal disorders and the deletion/insertion (D/I) polymorphism of the angiotensin converting enzyme (ACE) gene. Methods Case-control studies were combined, using the Mantel-Haenszel approach. Joint P values for continuous variables were calculated by Stouffer's method. Continuous measurements reported in different units were expressed on a percentage scale using the within-study mean of the II genotype as the denominator. Results The computerized database used for this analysis included 145 reports with an overall sample size of 49 959 subjects. Overall, possession of the D allele was associated with an increased risk of atherosclerotic and renal microvascular complications. In comparison with the II reference group, the excess risk in DD homozygotes (P < 0.001) was 32% for coronary heart disease (CHD; 30 studies), 45% for myocardial infarction (20 studies), 94% for stroke (five studies) and 56% for diabetic nephropathy (11 studies). The corresponding risk in DI heterozygotes amounted to 11% (P = 0.02), 13% (P = 0.02), 22% (P = 0.10) and 40% (P < 0.001), respectively. Hypertension (23 studies), left ventricular hypertrophy (five studies), hypertrophic or dilated cardiomyopathy (eight studies) and diabetic retinopathy (two studies) were not related to the DI polymorphism. Publication bias was observed for CHD, myocardial infarction and microvascular nephropathy, but not hypertension. In studies with DNA amplification in the presence of insertion-specific primers, the risk associated with the DD genotype increased to 150% [95% confidence interval (CI) 76-256; four studies] for diabetic nephropathy, but decreased to 12% (95% CI -3 to 28; seven studies) for CHD and 14% (95% CI -6 to 37; four studies) for myocardial infarction. On the other hand, the pooled odds ratios did not materially change if the metaanalysis was limited to articles published in journals with an impact factor of at least 4. Furthermore, compared with the II control group, the circulating ACE levels (29 studies) were raised 58 and 31% (P < 0.001) in DD and DI subjects, respectively. In contrast, plasma renin (10 studies), systolic and diastolic blood pressure (46 studies) and body mass index (30 studies) were not associated with the D allele. Conclusion The D allele is not associated with hypertension, but behaves as a marker of atherosclerotic cardiovascular complications and diabetic nephropathy. These associations do not necessarily imply a causal relationship and may have been inflated by publication bias. Nevertheless, their possible therapeutic implications may be subject to further investigation in prospective (intervention) studies. (C) Rapid Science Publishers ISSN 0263-6352.
引用
收藏
页码:1579 / 1592
页数:14
相关论文
共 50 条
  • [1] The deletion/insertion polymorphism of the angiotensin converting enzyme gene and risk of cardiovascular and renal diseases
    Kusnetsova, T
    Staessen, JA
    Wang, JG
    Petrov, V
    Soubrier, F
    Vlietinck, R
    Fagard, R
    Voevoda, M
    [J]. KARDIOLOGIYA, 1998, 38 (07) : 61 - 75
  • [2] The deletion/insertion polymorphism of the ACE gene and cardiovascular-renal risk.
    Staessen, JA
    Wang, J
    Ginocchio, G
    Petrov, V
    Saavedra, AP
    Soubrier, F
    Vlietinck, R
    Fagard, R
    [J]. HYPERTENSION, 1997, 30 (04) : 16 - 16
  • [3] Angiotensin Converting Enzyme Gene Insertion/Deletion Polymorphism and Cardiovascular DiseaseTherapeutic Implications
    Tianhua Niu
    Xiu Chen
    Xiping Xu
    [J]. Drugs, 2002, 62 : 977 - 993
  • [4] Insertion/Deletion Polymorphism of the Angiotensin Converting Enzyme Gene and Breast Cancer Risk
    Javaid, Naila Khatija
    Fathima, Husna
    Abdulla, Gulnaz
    Al-Ammari, Abeer Saleh
    Abbasi, Fatma Ahmad
    [J]. FASEB JOURNAL, 2010, 24
  • [6] Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease - Therapeutic implications
    Niu, TH
    Chen, X
    Xu, XP
    [J]. DRUGS, 2002, 62 (07) : 977 - 993
  • [7] Angiotensin converting enzyme gene insertion/deletion polymorphism in sarcoidosis
    Kim, TS
    Hong, HY
    Kim, CJ
    Lee, I
    [J]. LABORATORY INVESTIGATION, 2003, 83 (01) : 297A - 297A
  • [8] An insertion deletion polymorphism in the angiotensin converting enzyme gene and stroke
    Lee, DH
    Choi, JC
    Park, MK
    Han, JK
    [J]. NEUROLOGY, 1999, 52 (06) : A509 - A509
  • [9] Angiotensin converting enzyme gene insertion/deletion polymorphism in sarcoidosis
    Kim, TS
    Hong, HY
    Kim, CJ
    Lee, I
    [J]. MODERN PATHOLOGY, 2003, 16 (01) : 297A - 297A
  • [10] Angiotensin-converting enzyme gene insertion/deletion polymorphism and breast cancer risk
    Ladd, AMGZ
    Vásquez, AA
    Sayed-Tabatabaei, FA
    Coebergh, JW
    Hofman, A
    Njajou, O
    Stricker, B
    van Duijn, C
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (09) : 2143 - 2146